Eng-Eong Ooi

List of Publications by Year in descending order

232 papers	14,464 citations	18479 62 h-index	27402 106 g-index
257 all docs	257 docs citations	257 times ranked	20987 citing authors

#	Article	IF	Citations
1	SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 2020, 584, 457-462.	27.8	1,744
2	Dengue. Lancet, The, 2019, 393, 350-363.	13.7	420
3	Dengue Prevention and 35 Years of Vector Control in Singapore. Emerging Infectious Diseases, 2006, 12, 887-893.	4.3	378
4	Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science, 2015, 350, 217-221.	12.6	338
5	Etiology of Severe Non-malaria Febrile Illness in Northern Tanzania: A Prospective Cohort Study. PLoS Neglected Tropical Diseases, 2013, 7, e2324.	3.0	319
6	A Dynamic Immune Response Shapes COVID-19 Progression. Cell Host and Microbe, 2020, 27, 879-882.e2.	11.0	271
7	Dengue Prevention and 35 Years of Vector Control in Singapore. Emerging Infectious Diseases, 2006, 12, 887-893.	4.3	271
8	IL-1Î², IL-6, and RANTES as Biomarkers of Chikungunya Severity. PLoS ONE, 2009, 4, e4261.	2.5	249
9	Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs. Emerging Infectious Diseases, 2004, 10, 581-586.	4.3	209
10	The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody. Science Translational Medicine, 2012, 4, 139ra83.	12.4	200
11	Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infectious Diseases, The, 2014, 14, 706-715.	9.1	187
12	Decision Tree Algorithms Predict the Diagnosis and Outcome of Dengue Fever in the Early Phase of Illness. PLoS Neglected Tropical Diseases, 2008, 2, e196.	3.0	181
13	Update on Dengue: Epidemiology, Virus Evolution, Antiviral Drugs, and Vaccine Development. Current Infectious Disease Reports, 2010, 12, 157-164.	3.0	176
14	Naturally Acquired HumanPlasmodium knowlesiInfection, Singapore. Emerging Infectious Diseases, 2008, 14, 814-816.	4.3	175
15	Profiles of Antibody Responses against Severe Acute Respiratory Syndrome Coronavirus Recombinant Proteins and Their Potential Use as Diagnostic Markers. Vaccine Journal, 2004, 11, 362-371.	2.6	163
16	Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infectious Diseases, The, 2011, 11, 677-683.	9.1	162
17	Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cadernos De Saude Publica, 2009, 25, S115-S124.	1.0	158
18	Dengue virus activates cGAS through the release of mitochondrial DNA. Scientific Reports, 2017, 7, 3594.	3.3	156

#	Article	IF	Citations
19	Early TÂcell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med, 2021, 2, 682-688.e4.	4.4	152
20	A Novel Severe Acute Respiratory Syndrome Coronavirus Protein, U274, Is Transported to the Cell Surface and Undergoes Endocytosis. Journal of Virology, 2004, 78, 6723-6734.	3.4	149
21	Current Status of Dengue Therapeutics Research and Development. Journal of Infectious Diseases, 2017, 215, S96-S102.	4.0	144
22	Cost-Effective Real-Time Reverse Transcriptase PCR (RT-PCR) To Screen for Dengue Virus followed by Rapid Single-Tube Multiplex RT-PCR for Serotyping of the Virus. Journal of Clinical Microbiology, 2007, 45, 935-941.	3.9	134
23	Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12479-12484.	7.1	132
24	Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Research, 2011, 92, 453-460.	4.1	130
25	In vitro inhibition of human influenza A virus replication by chloroquine. Virology Journal, 2006, 3, 39.	3.4	128
26	Serum Metabolome and Lipidome Changes in Adult Patients with Primary Dengue Infection. PLoS Neglected Tropical Diseases, 2013, 7, e2373.	3.0	128
27	The 5â€² and 3â€² Untranslated Regions of the Flaviviral Genome. Viruses, 2017, 9, 137.	3.3	126
28	Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Cell, 2015, 162, 493-504.	28.9	111
29	A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Molecular Therapy, 2021, 29, 1970-1983.	8.2	111
30	The Early Clinical Features of Dengue in Adults: Challenges for Early Clinical Diagnosis. PLoS Neglected Tropical Diseases, 2011, 5, e1191.	3.0	109
31	Chikungunya and Dengue Fever among Hospitalized Febrile Patients in Northern Tanzania. American Journal of Tropical Medicine and Hygiene, 2012, 86, 171-177.	1.4	109
32	Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore. PLoS Neglected Tropical Diseases, 2011, 5, e1426.	3.0	106
33	Evaluation of the NS1 Rapid Test and the WHO Dengue Classification Schemes for Use as Bedside Diagnosis of Acute Dengue Fever in Adults. American Journal of Tropical Medicine and Hygiene, 2011, 84, 224-228.	1.4	105
34	The C-terminal 50 Amino Acid Residues of Dengue NS3 Protein Are Important for NS3-NS5 Interaction and Viral Replication. Journal of Biological Chemistry, 2015, 290, 2379-2394.	3.4	105
35	Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine, 2020, 55, 102768.	6.1	105
36	Structure mapping of dengue and Zika viruses reveals functional long-range interactions. Nature Communications, 2019, 10, 1408.	12.8	104

#	Article	IF	Citations
37	Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respiratory Research, 2006, 7, 126.	3.6	103
38	Proliferative growth of SARS coronavirus in Vero E6 cells. Journal of General Virology, 2003, 84, 3291-3303.	2.9	102
39	Dengue subgenomic flaviviral RNA disrupts immunity in mosquito salivary glands to increase virus transmission. PLoS Pathogens, 2017, 13, e1006535.	4.7	101
40	Seroepidemiology of Human Enterovirus 71, Singapore. Emerging Infectious Diseases, 2002, 8, 995-997.	4.3	99
41	Reconstructing historical changes in the force of infection of dengue fever in Singapore: implications for surveillance and control. Bulletin of the World Health Organization, 2008, 86, 187-196.	3.3	99
42	First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies. PLoS Pathogens, 2014, 10, e1004031.	4.7	98
43	Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2722-2727.	7.1	98
44	Diagnosis of dengue: an update. Expert Review of Anti-Infective Therapy, 2012, 10, 895-907.	4.4	97
45	Early Dengue infection and outcome study (EDEN) - study design and preliminary findings. Annals of the Academy of Medicine, Singapore, 2006, 35, 783-9.	0.4	90
46	Genomic Epidemiology of a Dengue Virus Epidemic in Urban Singapore. Journal of Virology, 2009, 83, 4163-4173.	3.4	89
47	Serum Proteome and Cytokine Analysis in a Longitudinal Cohort of Adults with Primary Dengue Infection Reveals Predictive Markers of DHF. PLoS Neglected Tropical Diseases, 2012, 6, e1887.	3.0	89
48	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. Journal of Clinical Investigation, 2021, 131, .	8.2	89
49	Molecular Typing of Salmonella enterica Serovar Typhi Isolates from Various Countries in Asia by a Multiplex PCR Assay on Variable-Number Tandem Repeats. Journal of Clinical Microbiology, 2003, 41, 4388-4394.	3.9	87
50	Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Research, 2012, 96, 32-35.	4.1	87
51	Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. Journal of Medical Microbiology, 2008, 57, 508-515.	1.8	83
52	Inhibition of Megakaryocyte Development in the Bone Marrow Underlies Dengue Virus-Induced Thrombocytopenia in Humanized Mice. Journal of Virology, 2013, 87, 11648-11658.	3.4	78
53	A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infectious Diseases, 2004, 4, 34.	2.9	77
54	Dengue seroepidemiology in Singapore. Lancet, The, 2001, 357, 685-686.	13.7	75

#	Article	IF	Citations
55	Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nature Microbiology, 2016, 1, 16164.	13.3	75
56	Assessing the epidemiological effect of wolbachia for dengue control. Lancet Infectious Diseases, The, 2015, 15, 862-866.	9.1	73
57	Early events of SARS coronavirus infection in vero cells. Journal of Medical Virology, 2003, 71, 323-331.	5.0	72
58	A method for full genome sequencing of all four serotypes of the dengue virus. Journal of Virological Methods, 2010, 169, 202-206.	2.1	72
59	Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans. PLoS Pathogens, 2010, 6, e1001051.	4.7	72
60	The Core and Accessory Genomes of Burkholderia pseudomallei: Implications for Human Melioidosis. PLoS Pathogens, 2008, 4, e1000178.	4.7	71
61	Dengue Virus Activates Polyreactive, Natural IgG B Cells after Primary and Secondary Infection. PLoS ONE, 2011, 6, e29430.	2.5	69
62	Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. Science Advances, 2018, 4, eaar4297.	10.3	69
63	Serum Metabolomics Reveals Serotonin as a Predictor of Severe Dengue in the Early Phase of Dengue Fever. PLoS Neglected Tropical Diseases, 2016, 10, e0004607.	3.0	69
64	Host Cell Transcriptome Profile during Wild-Type and Attenuated Dengue Virus Infection. PLoS Neglected Tropical Diseases, 2013, 7, e2107.	3.0	68
65	Research on Dengue During World War II Revisited. American Journal of Tropical Medicine and Hygiene, 2014, 91, 1203-1217.	1.4	68
66	Characterization of a Unique Group-Specific Protein (U122) of the Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2004, 78, 7311-7318.	3.4	67
67	Structural and Biological Diversity of Lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Vaccine Journal, 2009, 16, 1420-1428.	3.1	66
68	The C-terminal 18 Amino Acid Region of Dengue Virus NS5 Regulates its Subcellular Localization and Contains a Conserved Arginine Residue Essential for Infectious Virus Production. PLoS Pathogens, 2016, 12, e1005886.	4.7	66
69	Preventing Dengue Epidemics during the COVID-19 Pandemic. American Journal of Tropical Medicine and Hygiene, 2020, 103, 570-571.	1.4	66
70	Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine, 2014, 32, 5041-5048.	3.8	63
71	Immunological Characterization of the Spike Protein of the Severe Acute Respiratory Syndrome Coronavirus. Journal of Clinical Microbiology, 2004, 42, 1570-1576.	3.9	61
72	Sulfated Polysaccharide, Curdlan Sulfate, Efficiently Prevents Entry/Fusion and Restricts Antibody-Dependent Enhancement of Dengue Virus Infection In Vitro: A Possible Candidate for Clinical Application. PLoS Neglected Tropical Diseases, 2013, 7, e2188.	3.0	61

#	Article	IF	Citations
73	Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. Lancet, The, 2017, 389, 1611-1618.	13.7	61
74	Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy. Antiviral Research, 2016, 127, 10-19.	4.1	60
75	Mutational dynamics of the SARS coronavirus in cell culture and human populations isolated in 2003. BMC Infectious Diseases, 2004, 4, 32.	2.9	58
76	New Dengue Virus Type 1 Genotype in Colombo, Sri Lanka. Emerging Infectious Diseases, 2011, 17, 2053-5.	4.3	55
77	Mild Illness Associated with Severe Acute Respiratory Syndrome Coronavirus Infection: Lessons from a Prospective Seroepidemiologic Study of Healthâ€Care Workers in a Teaching Hospital in Singapore. Journal of Infectious Diseases, 2004, 189, 642-647.	4.0	54
78	Characterization of early host responses in adults with dengue disease. BMC Infectious Diseases, 2011, 11, 209.	2.9	54
79	Microvesicles from malaria-infected red blood cells activate natural killer cells via MDA5 pathway. PLoS Pathogens, 2018, 14, e1007298.	4.7	54
80	An outbreak of primary dengue infection among migrant Chinese workers in Singapore characterized by prominent gastrointestinal symptoms and a high proportion of symptomatic cases. Journal of Clinical Virology, 2005, 33, 336-340.	3.1	53
81	Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection. PLoS Neglected Tropical Diseases, 2015, 9, e0004058.	3.0	53
82	Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0004851.	3.0	53
83	Detection of Severe Acute Respiratory Syndrome Coronavirus in Blood of Infected Patients. Journal of Clinical Microbiology, 2004, 42, 347-350.	3.9	51
84	Multilocus Sequence Types of Carbapenem-Resistant Pseudomonas aeruginosa in Singapore Carrying Metallo-Î²-Lactamase Genes, Including the Novel bla _{IMP-26} Gene. Journal of Clinical Microbiology, 2010, 48, 2563-2564.	3.9	50
85	Dengue Virus-Infected Dendritic Cells, but Not Monocytes, Activate Natural Killer Cells through a Contact-Dependent Mechanism Involving Adhesion Molecules. MBio, 2017, 8, .	4.1	50
86	A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine, 2009, 27, 1354-1364.	3.8	49
87	A label-free immunosensor for diagnosis of dengue infection with simple electrical measurements. Biosensors and Bioelectronics, 2010, 25, 1137-1142.	10.1	49
88	Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes. PLoS Neglected Tropical Diseases, 2015, 9, e0003947.	3.0	49
89	Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients. Journal of Infectious Diseases, 2017, 216, 1112-1121.	4.0	48
90	Microarray and real-time RT-PCR analyses of differential human gene expression patterns induced by severe acute respiratory syndrome (SARS) coronavirus infection of Vero cells. Microbes and Infection, 2005, 7, 248-259.	1.9	47

#	Article	IF	Citations
91	Analysis of Dengue Virus Genetic Diversity during Human and Mosquito Infection Reveals Genetic Constraints. PLoS Neglected Tropical Diseases, 2015, 9, e0004044.	3.0	47
92	Molecular determinants of plaque size as an indicator of dengue virus attenuation. Scientific Reports, 2016, 6, 26100.	3.3	47
93	The performance of RT-PCR compared with a rapid serological assay for acute dengue fever in a diagnostic laboratory. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 142-148.	1.8	46
94	Seroepidemiology of neutralizing antibodies to Japanese encephalitis virus in Singapore: continued transmission despite abolishment of pig farming?. Acta Tropica, 2004, 92, 187-191.	2.0	44
95	Development of Real-Time PCR Assays and Evaluation of Their Potential Use for Rapid Detection of Burkholderia pseudomallei in Clinical Blood Specimens. Journal of Clinical Microbiology, 2007, 45, 2894-2901.	3.9	44
96	Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virology Journal, 2008, 5, 130.	3.4	43
97	Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole. Journal of Antimicrobial Chemotherapy, 2008, 61, 674-678.	3.0	42
98	Cross-Reactivity and Anti-viral Function of Dengue Capsid and NS3-Specific Memory T Cells Toward Zika Virus. Frontiers in Immunology, 2018, 9, 2225.	4.8	41
99	Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes. Journal of Clinical Investigation, 2020, 130, 5223-5234.	8.2	41
100	Development of a Western Blot Assay for Detection of Antibodies against Coronavirus Causing Severe Acute Respiratory Syndrome. Vaccine Journal, 2004, 11, 417-422.	2.6	40
101	A simple method for Alexa Fluor dye labelling of dengue virus. Journal of Virological Methods, 2010, 167, 172-177.	2.1	40
102	Association between microsatellites within the human MHC and nasopharyngeal carcinoma. , 1997, 74, 229-232.		38
103	Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology, 2010, 406, 80-87.	2.4	38
104	Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med, 2022, 3, 104-118.e4.	4.4	38
105	Asymptomatic SARS-CoV-2 infection. Lancet Infectious Diseases, The, 2020, 20, 996-998.	9.1	36
106	Serial Metabolome Changes in a Prospective Cohort of Subjects with Influenza Viral Infection and Comparison with Dengue Fever. Journal of Proteome Research, 2017, 16, 2614-2622.	3.7	35
107	A systematic approach to the development of a safe live attenuated Zika vaccine. Nature Communications, 2018, 9, 1031.	12.8	35
108	Dengue vaccineâ€“induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies. JCI Insight, 2017, 2, .	5.0	35

#	Article	IF	Citations
109	Production of Infectious Dengue Virus in Aedes aegypti Is Dependent on the Ubiquitin Proteasome Pathway. PLoS Neglected Tropical Diseases, 2015, 9, e0004227.	3.0	35
110	Global spread of epidemic dengue: the influence of environmental change. Future Virology, 2009, 4, 571-580.	1.8	34
111	Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Review of Anti-Infective Therapy, 2015, 13, 1351-1360.	4.4	34
112	Induction of Human T-cell and Cytokine Responses Following Vaccination with a Novel Influenza Vaccine. Scientific Reports, 2018, 8, 18007.	3.3	33
113	Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection. Nature Medicine, 2019, 25, 1218-1224.	30.7	33
114	Dengue Virus Neutralization in Cells Expressing Fc Gamma Receptors. PLoS ONE, 2013, 8, e65231.	2.5	33
115	A T164S mutation in the dengue virus NS1 protein is associated with greater disease severity in mice. Science Translational Medicine, 2019, 11, .	12.4	32
116	Molecular Analysis of Serum and Bronchoalveolar Lavage in a Mouse Model of Influenza Reveals Markers of Disease Severity That Can Be Clinically Useful in Humans. PLoS ONE, 2014, 9, e86912.	2.5	32
117	Dengue: an update on treatment options. Future Microbiology, 2015, 10, 2017-2031.	2.0	31
118	Identification and characterization of host proteins bound to dengue virus 3â€² UTR reveal an antiviral role for quaking proteins. Rna, 2018, 24, 803-814.	3.5	31
119	Effect of increasing age on the trend of dengue and dengue hemorrhagic fever in Singapore. International Journal of Infectious Diseases, 2003, 7, 231-232.	3.3	30
120	An Adjuvant for the Induction of Potent, Protective Humoral Responses to an H5N1 Influenza Virus Vaccine with Antigen-Sparing Effect in Mice. Journal of Virology, 2010, 84, 8639-8649.	3.4	30
121	Unfolded protein response (UPR) gene expression during antibody-dependent enhanced infection of cultured monocytes correlates with dengue disease severity. Bioscience Reports, 2011, 31, 221-230.	2.4	30
122	A Prospective Clinical Study on the Use of Reverse Transcription-Polymerase Chain Reaction for the Early Diagnosis of Dengue Fever. Journal of Molecular Diagnostics, 2006, 8, 613-616.	2.8	29
123	Cell surface Î±2,3-linked sialic acid facilitates Zika virus internalization. Emerging Microbes and Infections, 2019, 8, 426-437.	6.5	29
124	Acquired carbapenemases in Enterobactericeae in Singapore, 1996-2012. Pathology, 2013, 45, 600-603.	0.6	28
125	The Combination of Type I IFN, TNF-Î±, and Cell Surface Receptor Engagement with Dendritic Cells Enables NK Cells To Overcome Immune Evasion by Dengue Virus. Journal of Immunology, 2014, 193, 5065-5075.	0.8	28
126	Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope. Cell Host and Microbe, 2018, 23, 618-627.e6.	11.0	28

#	Article	IF	Citations
127	Gut Ruminococcaceae levels at baseline correlate with risk of antibiotic-associated diarrhea. IScience, 2022, 25, 103644.	4.1	28
128	Healthcare Worker Seroconversion in SARS Outbreak. Emerging Infectious Diseases, 2004, 10, 249-250.	4.3	27
129	Innate Immune Responses of Pulmonary Epithelial Cells to Burkholderia pseudomallei Infection. PLoS ONE, 2009, 4, e7308.	2.5	27
130	Presence of hemagglutination inhibition and neutralization antibodies to Japanese encephalitis virus in wild pigs on an offshore island in Singapore. Acta Tropica, 2002, 81, 233-236.	2.0	26
131	Preparing for introduction of a dengue vaccine: Recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine, 2011, 29, 9417-9422.	3.8	26
132	Microneedleâ€based intradermal delivery of stabilized dengue virus. Bioengineering and Translational Medicine, 2019, 4, e10127.	7.1	26
133	Serum Metabolomics Investigation of Humanized Mouse Model of Dengue Virus Infection. Journal of Virology, 2017, 91, .	3.4	25
134	Serum metabolome changes in adult patients with severe dengue in the critical and recovery phases of dengue infection. PLoS Neglected Tropical Diseases, 2018, 12, e0006217.	3.0	25
135	Acinetobacter calcoaceticusâ€“Acinetobacter baumannii complex species in clinical specimens in Singapore. Epidemiology and Infection, 2012, 140, 535-538.	2.1	24
136	A Human PrM Antibody That Recognizes a Novel Cryptic Epitope on Dengue E Glycoprotein. PLoS ONE, 2012, 7, e33451.	2.5	24
137	Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. Virology, 2013, 439, 34-41.	2.4	24
138	Economic Analysis of Pandemic Influenza Vaccination Strategies in Singapore. PLoS ONE, 2009, 4, e7108.	2.5	24
139	Chikungunya in Singapore: Imported Cases Among Travelers Visiting Friends and Relatives: Table 1. Journal of Travel Medicine, 2009, 16, 289-291.	3.0	23
140	Viral Manipulation of Host Inhibitory Receptor Signaling for Immune Evasion. PLoS Pathogens, 2016, 12, e1005776.	4.7	23
141	Rapid molecular typing of Burkholderia pseudomallei, isolated in an outbreak of melioidosis in Singapore in 2004, based on variable-number tandem repeats. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 687-692.	1.8	22
142	The 2007 dengue outbreak in Singapore. Epidemiology and Infection, 2010, 138, 958-961.	2.1	22
143	Positive epistasis between viral polymerase and the 3â€² untranslated region of its genome reveals the epidemiologic fitness of dengue virus. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11038-11047.	7.1	22
144	Adverse effects following antiâ€“COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes. PLoS Biology, 2022, 20, e3001643.	5.6	22

#	Article	IF	Citations
145	Development of a simplified assay for the detection of neutralizing antibodies to Japanese encephalitis virus. Journal of Virological Methods, 2001, 93, 43-47.	2.1	21
146	A highly divergent Encephalomyocarditis virus isolated from nonhuman primates in Singapore. Virology Journal, 2013, 10, 248.	3.4	21
147	The re-emergence of dengue in China. BMC Medicine, 2015, 13, 99.	5.5	21
148	Dengue virus compartmentalization during antibody-enhanced infection. Scientific Reports, 2017, 7, 40923.	3.3	21
149	Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein. PLoS Neglected Tropical Diseases, 2018, 12, e0006209.	3.0	21
150	Phase 1 Trial of a Therapeutic Antiâ€“Yellow Fever Virus Human Antibody. New England Journal of Medicine, 2020, 383, 452-459.	27.0	21
151	Temporal dynamics of the host molecular responses underlying severe COVID-19 progression and disease resolution. EBioMedicine, 2021, 65, 103262.	6.1	21
152	Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. Npj Vaccines, 2022, 7, 31.	6.0	21
153	Dysregulated metabolism underpins Zika-virus-infection-associated impairment in fetal development. Cell Reports, 2021, 37, 110118.	6.4	21
154	Novel Immunofluorescence Assay Using Recombinant Nucleocapsid-Spike Fusion Protein as Antigen To Detect Antibodies against Severe Acute Respiratory Syndrome Coronavirus. Vaccine Journal, 2005, 12, 321-328.	3.1	20
155	Persistent Dengue Infection in an Immunosuppressed Patient Reveals the Roles of Humoral and Cellular Immune Responses in Virus Clearance. Cell Host and Microbe, 2019, 26, 601-605.e3.	11.0	20
156	Evolution of Subgenomic RNA Shapes Dengue Virus Adaptation and Epidemiological Fitness. IScience, 2019, 16, 94-105.	4.1	20
157	Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection. MSphere, 2019, 4, .	2.9	20
158	Patient-Based Transcriptome-Wide Analysis Identify Interferon and Ubiquination Pathways as Potential Predictors of Influenza A Disease Severity. PLoS ONE, 2014, 9, e111640.	2.5	19
159	Therapeutic antibodies as a treatment option for dengue fever. Expert Review of Anti-Infective Therapy, 2013, 11, 1147-1157.	4.4	18
160	Tuberculous meningitis is a major cause of mortality and morbidity in adults with central nervous system infections in Kota Kinabalu, Sabah, Malaysia: an observational study. BMC Infectious Diseases, 2016, 16, 296.	2.9	18
161	Peridomestic Aedes malayensis and Aedes albopictus are capable vectors of arboviruses in cities. PLoS Neglected Tropical Diseases, 2017, 11, e0005667.	3.0	18
162	Japanese Encephalitis, Singapore. Emerging Infectious Diseases, 2006, 12, 525-526.	4.3	18

#	Article	IF	Citations
163	Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis. Journal of Clinical Virology, 2013, 56, 37-40.	3.1	17
164	Association Between Increased Vascular Nitric Oxide Bioavailability and Progression to Dengue Hemorrhagic Fever in Adults. Journal of Infectious Diseases, 2015, 212, 711-714.	4.0	17
165	Distribution ofAedesmosquitoes in the Kilimanjaro Region of northern Tanzania. Pathogens and Global Health, 2016, 110, 108-112.	2.3	17
166	Monkey malaria in humans: a diagnostic dilemma with conflicting laboratory data. American Journal of Tropical Medicine and Hygiene, 2009, 80, 927-8.	1.4	17
167	Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. Virology Journal, 2008, 5, 80.	3.4	16
168	Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies. Antiviral Research, 2012, 96, 340-343.	4.1	16
169	Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates. Antiviral Research, 2017, 144, 44-47.	4.1	16
170	Hypoxia enhances antibodyâ€dependent dengue virus infection. EMBO Journal, 2017, 36, 1348-1363.	7.8	16
171	Dengue pre-vaccination serology screening for the use of DengvaxiaÂ®. Journal of Travel Medicine, 2019, 26, .	3.0	16
172	Early molecular correlates of adverse events following yellow fever vaccination. JCI Insight, 2017, 2, .	5.0	16
173	Application of a targeted-enrichment methodology for full-genome sequencing of Dengue 1-4, Chikungunya and Zika viruses directly from patient samples. PLoS Neglected Tropical Diseases, 2019, 13, e0007184.	3.0	15
174	Hypoxia and viral infectious diseases. JCI Insight, 2021, 6, .	5.0	15
175	Discovery and Validation of Prognostic Biomarker Models to Guide Triage among Adult Dengue Patients at Early Infection. PLoS ONE, 2016, 11, e0155993.	2.5	14
176	Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicity. Npj Vaccines, 2019, 4, 27.	6.0	14
177	A Non-structural 1 Protein G53D Substitution Attenuates a Clinically Tested Live Dengue Vaccine. Cell Reports, 2020, 31, 107617.	6.4	14
178	A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection. Antiviral Research, 2021, 193, 105138.	4.1	14
179	Surveillance, prevention, and control of legionellosis in a tropical city-state. American Journal of Infection Control, 2005, 33, 286-291.	2.3	13
180	Oxygen: viral friend or foe?. Virology Journal, 2020, 17, 115.	3.4	13

#	Article	IF	Citations
181	Sequential immunization induces strong and broad immunity against all four dengue virus serotypes. Npj Vaccines, 2020, 5, 68.	6.0	13
182	Lack of association of dengue activity with haze. Epidemiology and Infection, 2010, 138, 962-967.	2.1	12
183	Scrub Typhus with Sepsis and Acute Respiratory Distress Syndrome. Journal of Clinical Microbiology, 2013, 51, 2787-2790.	3.9	12
184	The Lancet Commission on dengue and other Aedes-transmitted viral diseases. Lancet, The, 2020, 395, 1890-1891.	13.7	12
185	The rapid identification ofClostridium perfringensas the possible aetiology of a diarrhoeal outbreak using PCR. Epidemiology and Infection, 2008, 136, 1142-1146.	2.1	11
186	Antibiotic susceptibility of 50 clinical isolates of Burkholderia pseudomallei from Singapore. Journal of Antimicrobial Chemotherapy, 2006, 58, 1102-1103.	3.0	10
187	Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection. EBioMedicine, 2020, 61, 103028.	6.1	10
188	Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine. JCI Insight, 2021, 6, .	5.0	10
189	Visualizing Dengue Virus through Alexa Fluor Labeling. Journal of Visualized Experiments, 2011, , e3168.	0.3	9
190	Regarding "Dengue--How Best to Classify It". Clinical Infectious Diseases, 2012, 54, 1820-1821.	5.8	9
191	Augmentation of 5-lipoxygenase activity and expression during dengue serotype-2 infection. Virology Journal, 2013, 10, 322.	3.4	9
192	Asymptomatic dengue infection may trigger Guillainâ€BarrÃ© syndrome. Journal of the Peripheral Nervous System, 2016, 21, 375-377.	3.1	9
193	Genetic diversity of respiratory enteroviruses and rhinoviruses in febrile adults, Singapore, 2007â€2013. Influenza and Other Respiratory Viruses, 2020, 14, 67-71.	3.4	9
194	A potential silver lining of delaying the second dose. Nature Immunology, 2022, 23, 349-351.	14.5	8
195	Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity. Mikrochimica Acta, 2022, 189, 14.	5.0	8
196	A Report of Adult Human Adenovirus Infections in a Tertiary Hospital. Open Forum Infectious Diseases, 2017, 4, ofx053.	0.9	7
197	Attenuated dengue viruses are genetically more diverse than their respective wild-type parents. Npj Vaccines, 2021, 6, 76.	6.0	7
198	Target product profile for a dengue pre-vaccination screening test. PLoS Neglected Tropical Diseases, 2021, 15, e0009557.	3.0	7

#	Article	IF	Citations
199	Animal Coronavirus Diseases: Parallels with COVID-19 in Humans. Viruses, 2021, 13, 1507.	3.3	7
200	Revisiting dengue virus-mosquito interactions: molecular insights into viral fitness. Journal of General Virology, 2021, 102, .	2.9	7
201	Characteristics of acute febrile illness and determinants of illness recovery among adults presenting to Singapore primary care clinics. BMC Infectious Diseases, 2016, 16, 612.	2.9	6
202	Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore. Human Vaccines and Immunotherapeutics, 2017, 13, 551-560.	3.3	6
203	Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice. Frontiers in Immunology, 2019, 10, 1429.	4.8	6
204	The effects of aging on host resistance and disease tolerance to SARSâ€CoVâ€2 infection. FEBS Journal, 2021, 288, 5055-5070.	4.7	6
205	Disentangling etiologies of CNS infections in Singapore using multiple correspondence analysis and random forest. Scientific Reports, 2020, 10, 18219.	3.3	6
206	Repurposing Ivermectin as an Anti-dengue Drug. Clinical Infectious Diseases, 2021, 72, e594-e595.	5.8	6
207	Antimicrobial activity of cathelicidin peptides against Burkholderia pseudomallei, the causative agent of melioidosis. International Journal of Antimicrobial Agents, 2011, 38, 270-271.	2.5	5
208	Dengue and Dengue Hemorrhagic Fever. , 2011, , 504-510.		4
209	Higher Risk of Infection with Dengue at the Weekend among Male Singaporeans. American Journal of Tropical Medicine and Hygiene, 2012, 87, 1116-1118.	1.4	4
210	Dengue Virus Growth, Purification, and Fluorescent Labeling. Methods in Molecular Biology, 2014, 1138, 3-14.	0.9	4
211	Genomic signature of early T-cell response is associated with lower antibody titer threshold for sterilizing immunity. Antiviral Research, 2019, 166, 35-41.	4.1	4
212	The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial. Trials, 2015, 16, 147.	1.6	3
213	A Simple and Powerful Method for the Estimation of Intervention Effects on Serological Endpoints Using Paired Interval-Censored Data. Journal of Biopharmaceutical Statistics, 2015, 25, 124-136.	0.8	3
214	Dengue: An Expanding Neglected Tropical Disease. Neglected Tropical Diseases, 2019, , 65-84.	0.4	3
215	When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?. Vaccines, 2020, 8, 174.	4.4	3
216	Challenges in prevaccination screening for previous dengue infection. The Lancet Global Health, 2021, 9, e4-e5.	6.3	3

#	Article	IF	Citations
217	Hypertonic Saline Reduces Vascular Leakage in a Mouse Model of Severe Dengue. PLoS ONE, 2013, 8, e61621.	2.5	3
218	Optimal flexibility of the linker region of Zika virus NS5 methyltransferase-polymerase is critical for virus replication. Antiviral Research, 2021, 195, 105194.	4.1	3
219	Hyperinflammatory Syndrome, Natural Killer Cell Function, and Genetic Polymorphisms in the Pathogenesis of Severe Dengue. Journal of Infectious Diseases, 2022, 226, 1338-1347.	4.0	3
220	Evolution of Subgenomic RNA Shapes Dengue Virus Adaptation and Epidemiological Fitness. SSRN Electronic Journal, 0, , .	0.4	2
221	Viral genome-based Zika virus transmission dynamics in a paediatric cohort during the 2016 Nicaragua epidemic. EBioMedicine, 2021, 72, 103596.	6.1	2
222	A protocol to assess cellular bioenergetics in flavivirus-infected cells. STAR Protocols, 2022, 3, 101297.	1.2	2
223	Etiology of febrile respiratory infections in the general adult population in Singapore, 2007â€“2013. Heliyon, 2021, 7, e06329.	3.2	1
224	Association between microsatellites within the human MHC and nasopharyngeal carcinoma. International Journal of Cancer, 1997, 74, 229-232.	5.1	1
225	Cell Strain-Derived Induced Pluripotent Stem Cells as an Isogenic Approach To Investigate Age-Related Host Response to Flaviviral Infection. Journal of Virology, 2022, 96, JVI0173721.	3.4	1
226	Epidemiology, Outcomes and Prognosis of Central Nervous System Infections in Singapore. Preliminary results from The Singapore Neurologic Infections Programme (SNIP). Open Forum Infectious Diseases, 2017, 4, S303-S304.	0.9	0
227	2505. A Novel Mobile Phone Application for Remote Research Data Collection is Effective in Monitoring Chronic Sequelae After Acute Viral Infections. Open Forum Infectious Diseases, 2018, 5, S753-S753.	0.9	0
228	Dengue and Zika RNA-RNA Interactomes Reveal Virus Permissive and Restrictive Factors in Human Cells. SSRN Electronic Journal, 0, , .	0.4	0
229	Antibody sugars are bittersweet. Science, 2021, 372, 1041-1042.	12.6	0
230	Metabolic Processes Are Differentially Regulated During Wild-Type and Attenuated Dengue Virus Infection in Aedes aegypti. American Journal of Tropical Medicine and Hygiene, 2022, , .	1.4	0
231	Re: Dengue fever outbreak: prevention possible (author's reply). Annals of the Academy of Medicine, Singapore, 2013, 42, 484.	0.4	0
232	Reply to "Use of Prediction Models for Risk Analysis and Decision-Making in Public Health-The Catch-22 Conundrum". Annals of the Academy of Medicine, Singapore, 2016, 45, 367-8.	0.4	0